Novo Nordisk stock consolidates near $39.72 support amid mixed earnings and buyer support
Novo Nordisk (NVO) stock is trading at $40.24, posting a modest decline on the day. The price sits below its key short- and long-term moving averages, while holding above certain medium-term trend levels.
Highlights
- Novo Nordisk reported third-quarter adjusted operating profit up 27% at constant exchange rates to DKK 31,720 million, with stronger operational performance.
- Net profit for the period fell 16% to DKK 16.74 billion and adjusted net profit declined 12%, as margin or cost pressures persisted.
- Shares of Novo Nordisk are expected to trade between $38.98 and $41.5 over the next 2 to 3 days, with technical indicators showing a 75% probability of an upward move amid short-term indecision.
Margins pressured despite profit growth and aggressive share buybacks
Novo Nordisk reported a 27% jump in its third-quarter adjusted operating profit at constant exchange rates to DKK 31,720 million, reflecting stronger operational performance and improved cash flows, according to Globenewswire. Despite these gains, net profit for the period fell 16% year-over-year to DKK 16.74 billion and adjusted net profit dropped 12%, highlighting margin or cost pressures that temper the positive topline developments, as reported by Rttnews. Obesity sales expanded by 22% in the quarter, fueled primarily by continued strength in Wegovy. The company also repurchased 41.7 million B shares valued at DKK 11.56 billion under its ongoing buyback program, providing mechanical support for the share price.
Buy signals emerge amid resistance at key technical thresholds
On the technical front, NVO is positioned below its MA-20 and above the MA-50, while still trading under the long-term MA-200. Immediate support is marked by the Ichimoku Kijun at $39.72. MACD is signaling strong buy momentum, with ADX also indicating a buying bias. Oscillator signals remain mixed: RSI is neutral, Stoch RSI is oversold, and CCI is neutral on the h1 chart. Intraday, Bull/Bear Power is slightly positive while the Awesome Oscillator is neutral, reflecting moderate buyer dominance but with ongoing indecision due to mid-range price action and volatility.
Upside potential prevails as breakout risks shape near-term outcome
Looking ahead to the next 23 trading days, NVO is expected to fluctuate within a typical volatility band between $38.98 and $41.5. There is a 75% probability of prices moving higher out of this corridor and a 25% chance of a downside break. The baseline scenario is for consolidation within this range, with the bullish scenario contingent on a breakout above resistance, and the bearish outcome materializing if the price falls below support at $39.72.
Earlier, analysts noted that Novo Nordisk was exhibiting near-term strength while contending with longer-term resistance, with upcoming earnings positioned as a potential catalyst for further movement. The latest results add nuance by highlighting improved operating performance alongside margin pressures, making the interplay between technical support at $39.72 and the next breakout level especially significant for near-term trading strategy.